Skip to main content
. 2019 May 29;59(9):3002–3025. doi: 10.1111/trf.15344

Table 1.

Reasons for slow adoption of PR PLTs in the United States

Current safety of the volunteer blood supply
Success of surveillance and screening in dealing with emerging pathogens
Inability of current technologies to inactivate all agents (small nonencapsulated viruses, spores, high titers of virus, and prions)
Efficacy concerns
No single method to treat all components
Regulatory requirements
Cost